Pharmaceuticals News and Research

RSS

InteRNA, Silence partner to develop novel microRNA therapeutics for cancer

Silence Therapeutics plc, a leading global RNA interference (RNAi) therapeutics company, and InteRNA Technologies B.V., a biopharmaceutical company developing pathway targeted microRNA-based therapeutics for cancer, today announce that they have entered into an agreement to develop novel microRNA therapeutics for the treatment of cancer.

12 Sep 2011

HPV vaccination updates

Texas Governor Rick Perry's GOP rivals sharply criticized him during Wednesday night's debate over his 2007 executive order mandating that teenage girls be vaccinated to prevent cervical cancer. The move had drawn strong opposition at the time from social conservatives and was later overturned by the state Legislature.

9 Sep 2011

AARP strategist moves on to health care coalition

After 27 years at AARP, John Rother will move on to head up the National Coalition on Health Care. He says his new position will give him a platform to take on health care costs, as issue he views as central to the nation.

9 Sep 2011

Rich countries watering down NCD commitments to appease multinational companies

Professor and director of the WHO Collaborating Centre for Obesity Prevention at Deakin University in Australia, examines how "rich countries, ... particularly the U.S. and European Union but also Australia, Canada and New Zealand, ... are joining forces with tobacco, food, alcohol and pharmaceutical corporations to water down commitments that might flow from" this month's U.N. High-level Meeting on Non-Communicable Diseases (NCDs) in New York.

9 Sep 2011

'Super committee' faces big challenges, lots of input from stakeholders

In order to lay out some specific options from which the panel might extract savings, House Ways and Means Democrats have provided a list of Medicare trims.

9 Sep 2011

Docs' group pushes for changes to Medicare payment setting panel

Meanwhile, other news outlets report on the challenges private practice physicians face in serving their patients and their own bottom lines, and ProPublica explores drug company payments to doctors.

9 Sep 2011

AstraZeneca Canada introduces new NEXIUM Patient Support program

Canadian pharmaceutical company, AstraZeneca Canada Inc., has introduced a new NEXIUM® Patient Support program designed to give physicians and pharmacists the ability to take cost out of the equation in the patient's choice between NEXIUM® tablets and a generic esomeprazole product.

9 Sep 2011

Patheon third quarter revenues increase 5.8% to $172.7 million

Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today: Details of Patheon's new corporate strategy, including an initial heavy focus on strengthening the company's core operations.

9 Sep 2011

FDA grants final approval for Mylan's Promethazine HCl Tablets

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Promethazine Hydrochloride (HCl) Tablets USP, 12.5 mg, 25 mg and 50 mg. Promethazine HCl Tablets are used to relieve the symptoms of certain allergic reactions, such as perennial and seasonal allergic rhinitis.

9 Sep 2011

Astex selects PharmaVentures to assist in divesment of CMC & Formulation Facility

PharmaVentures Limited, experts in deals and alliances, are pleased to announce that they have been engaged by leading drug discovery company, Astex Pharmaceuticals to seek a buyer for an established full service CMC & Formulation Facility in Pleasanton, California. The engagement will utilise PharmaVentures' asset divestment expertise in the life sciences sector.

9 Sep 2011

Cardiovascular and Renal Drugs Advisory Committee recommends FDA approval of J&JPRD's rivaroxaban

Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD) announced today that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee recommended approval of rivaroxaban, a novel, once-daily, oral anticoagulant, for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.

9 Sep 2011

Elusys receives federal contract to develop prophylactic treatment against anthrax

Elusys Therapeutics, Inc., a biopharmaceutical company developing biodefense countermeasures, announced today that it has been awarded the first U.S. Government contract to develop an anti-toxin for pre- and post-exposure prophylaxis (PEP) use via intramuscular injection.

9 Sep 2011

Sagene completes SPI-1972 pre-IND meeting with FDA for erectile dysfunction

Sagene Pharmaceuticals, Inc., a biopharmaceutical company focused on developing combinations of FDA-approved drugs to treat diseases associated with aging, has completed a pre-IND meeting with the Division of Reproductive and Urologic Products of the FDA to discuss the development plan for SPI-1972, a dual-action combination treatment for erectile dysfunction.

9 Sep 2011

Bristol-Myers Squibb acquires Amira Pharmaceuticals

Bristol-Myers Squibb Company announced today that it has completed its previously announced acquisition of privately held Amira Pharmaceuticals, Inc., a small-molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases.

9 Sep 2011

Auxilium reports positive data from XIAFLEX retrospective commercial patient chart review

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced that positive data from a retrospective commercial patient chart review of XIAFLEX (collagenase clostridium histolyticum) used for the treatment of adult Dupuytren's contracture patients with a palpable cord are available via e-posters at the American Society for Surgery of the Hand meeting in Las Vegas.

8 Sep 2011

Japan's CCRC to implement Medidata Rave's EDC/CDM system

Medidata Solutions, a leading global provider of SaaS-based clinical development solutions, today announced that the Chiba University Hospital Clinical Research Center, one of Japan's leading clinical research institutions, has chosen Medidata Rave as its electronic data capture (EDC) and clinical data management (CDM) solution.

8 Sep 2011

EC grants orphan drug status for Santen's sirolimus to treat chronic non-infectious uveitis

Santen Inc., the U.S. subsidiary of global ophthalmic pharmaceutical company Santen Pharmaceutical Co., Ltd. today announced the European Commission (EC) has granted orphan drug status for sirolimus (DE-109) for the treatment of chronic non-infectious uveitis.

From Santen Pharmaceutical Co., Ltd. 8 Sep 2011

Suit accuses generic drugmakers of overcharging Medicaid

Three generic drugmakers are being accused in a whistleblower lawsuit of scheming to overcharge the government by tens of millions of dollars for medicines.

8 Sep 2011

Abnormal levels of lysophosphatidic acid can trigger congenital hydrocephalus

Scientists at The Scripps Research Institute have found what may be a major cause of congenital hydrocephalus, one of the most common neurological disorders of childhood that produces mental debilitation and sometimes death in premature and newborn children.

8 Sep 2011

Pharnext puts together €2.5M to fund development of Pleodrug for Charcot-Marie-Tooth disease

Pharnext SAS, a biopharmaceutical company specializing in the development of innovative treatments based on Pleotherapy for severe neurological diseases, today announced that it has put together a €2.5 million round of financing (corresponding to a pre-money company valuation of €60 million).

8 Sep 2011